UK MHRA Postpones April Target Date For New Device Fees
This article was originally published in Clinica
Executive Summary
The UK Medicines and Healthcare Products Regulatory Agency is postponing its April target date for introducing a new fee-based system for regulating medical devices.
You may also be interested in...
IVD UK Spring Meeting: The Costly But Necessary Route To IVDR Compliance
Second of two articles covering discussion at the spring 2017 meeting of the British In Vitro Diagnostics Association: Not all will survive unscathed as the EU IVD Regulation becomes an operational reality.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.